Ipamorelin

Overview

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 and a molecular weight of 711.85 Da. First described in the late 1990s, it was characterized as the first truly selective growth hormone releasing peptide (GHRP), distinguished from earlier secretagogues such as GHRP-2 and GHRP-6 by its remarkably clean endocrine profile.

Ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor activated by endogenous ghrelin. However, unlike ghrelin and less selective GHRPs, ipamorelin stimulates growth hormone release without significantly affecting cortisol, prolactin, aldosterone, or adrenocorticotropic hormone (ACTH) levels, even at doses exceeding 200-fold its ED50 for GH release.

Mechanism of Action

Ipamorelin binds to GHS-R1a receptors located primarily in the anterior pituitary gland and hypothalamus. Receptor activation triggers intracellular calcium signaling cascades in somatotroph cells, leading to pulsatile growth hormone release that mimics physiological secretion patterns.

The selectivity of ipamorelin is its defining pharmacological characteristic. While GHRP-6 and GHRP-2 activate multiple receptor subtypes and stimulate appetite (via ghrelin-like activity), cortisol release (via ACTH stimulation), and prolactin secretion, ipamorelin demonstrates high specificity for the GH-releasing pathway. This selectivity is attributed to its modified peptide structure, which achieves optimal binding geometry at GHS-R1a without engaging the broader neuroendocrine signaling cascades associated with less selective compounds.

Peak plasma GH concentrations occur approximately 20-30 minutes following subcutaneous administration, with the peptide itself exhibiting a plasma half-life of approximately 2 hours.

Research Evidence

The foundational pharmacological characterization of ipamorelin was published by Raun et al. (PMID: 9849822), establishing it as the first selective growth hormone secretagogue. This study demonstrated dose-dependent GH release without concomitant changes in ACTH, cortisol, or prolactin, distinguishing ipamorelin from all previously described GHRPs.

A Phase II randomized controlled trial (Beck et al., 2014; PMID: 25331030) evaluated ipamorelin for postoperative ileus management in 87 patients following bowel resection surgery. This proof-of-concept study represented the most rigorous published human clinical data for ipamorelin, examining its prokinetic effects via ghrelin receptor agonism in the gastrointestinal tract.

Preclinical work by Venkova et al. (PMID: 19289567) demonstrated that ipamorelin accelerates gastrointestinal transit and ameliorates symptoms in rodent models of postoperative ileus, providing mechanistic support for its GI-targeted applications.

Animal studies have also investigated ipamorelin's effects on bone mineral density, lean body mass, and adipose tissue distribution, with findings suggesting anabolic effects consistent with enhanced GH/IGF-1 axis activity.

Potential Applications

• Growth hormone deficiency: Selective GH stimulation without cortisol or prolactin elevation may offer advantages over less selective secretagogues
• Postoperative ileus: Ghrelin receptor agonism in the GI tract to promote gastrointestinal motility recovery after abdominal surgery
• Body composition: Preclinical data suggesting improvements in lean mass and reduction of adiposity via enhanced GH pulsatility
• Bone health: Animal model evidence of increased bone mineral content and density with chronic administration
• Age-related GH decline: Investigation as a potential intervention for somatopause, the progressive decline of GH secretion with aging

Safety Considerations

In clinical trials, ipamorelin has demonstrated a favorable safety profile relative to less selective growth hormone secretagogues. The absence of significant cortisol, ACTH, and prolactin stimulation reduces the risk of adrenal axis perturbation and hyperprolactinemia-related effects observed with GHRP-2 and GHRP-6.

Reported adverse effects in clinical settings include transient injection site reactions, mild headache, and occasional flushing. As with all GH secretagogues, theoretical concerns include potential effects on glucose homeostasis (GH is a counter-regulatory hormone), and individuals with active malignancies should be aware that GH/IGF-1 signaling may influence tumor biology.

Human clinical data for ipamorelin remains limited to Phase I/II trials, and no regulatory approval has been granted for any therapeutic indication. The majority of available evidence derives from preclinical rodent models, and findings should not be extrapolated to clinical recommendations.